Erste Asset Management Gmb H Prometheus Biosciences, Inc. Transaction History

Erste Asset Management Gmb H

  • $8.35 Trillion
  • Q3 2024

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2023

Nov 26, 2024
SELL
N/A
-8,800 Closed
0 $0
Q2 2023

Nov 26, 2024
SELL
$0.0 - $199.92 $0 - $1.76 Million
-8,800 Closed
0 $0
Q3 2022

Nov 26, 2024
BUY
$28.17 - $59.01 $247,896 - $519,288
8,800 New
8,800 $506 Million
Q2 2022

Nov 26, 2024
BUY
$22.39 - $38.94 $197,032 - $342,672
8,800 New
8,800 $245 Million
Q1 2022

Nov 22, 2024
BUY
$30.13 - $50.0 $265,144 - $440,000
8,800 New
8,800 $330 Million

Others Institutions Holding RXDX

# of Institutions
2
Shares Held
29.6K
Call Options Held
0
Put Options Held
0
View Full List

About Prometheus Biosciences, Inc.

RXDX Quotes by TradingView
  • Ticker RXDX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 40,904,100
  • Description
  • Prometheus Biosciences, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of novel therapeutics and companion diagnostics products for the treatment of inflammatory bowel diseases (IBD). Its lead product includes PRA023, a humanized IgG1 monoclonal antibody (mAb), which is in Phase IIa clinical trial...
More about RXDX
Track This Portfolio

Track Erste Asset Management Gmb H Portfolio

Follow Erste Asset Management Gmb H and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Erste Asset Management Gmb H, based on Form 13F filings with the SEC.

News

Stay updated on Erste Asset Management Gmb H with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email